Table 11.
Dosage of THC and CBD administered with dominant THC medical cannabis to fibromyalgia patients
| Patient | THC-dominant MC (Bedrocan, FM1, Pedanios), N= 18 | |||
|---|---|---|---|---|
| Decoction | Oil extract | |||
| THC (mg) | CBD (mg) | THC (mg) | CBD (mg) | |
| Patient #1 | 22 | 0 | ||
| Patient #2 | 132 | 0 | ||
| Patient #3 | 22 | 0 | ||
| Patient #4 | 9.69 | 0 | ||
| Patient #5 | 66 | 0 | ||
| Patient #6 | 100.8 | 2.4 | ||
| Patient #7 | ||||
| Patient #8 | 53.4 | 1.2 | ||
| Patient #9 | 22 | 0 | ||
| Patient #10 | ||||
| Patient #11 | 99 | 0 | 34.2 | 0 |
| Patient #12 | 52.8 | 0.3 | ||
| Patient #13 | 46.2 | 0 | ||
| Patient #14 | 44 | 0 | 8.55 | 0 |
| Patient #15 | 22 | 0 | ||
| Patient #16 | 35.2 | 0 | ||
| Patient #17 | ||||
| Patient #18 | ||||
| Median | 46.2 | 0 | 9.7 | 0 |
| IQR | 60.5 | 0.15 | 25.65 | 0 |
| Mean | 55.2 | 0.3 | 17.5 | 2 |
| ± SD | 35.4 | 0.7 | 14.5 | 1.3 |
MC medical cannabis, THC Δ-9-tetrahydrocannabinol, CBD cannabidiol, N number of patients, IQR interquartile range, ± plus/minus, SD standard deviation. The table shows the quantity of Δ-9-tetrahydrocannabinol and cannabidiol administered with THC-dominant medical cannabis to 18 patients with fibromyalgia syndrome treated with medical cannabis for at least 3 months at an Italian pain clinic. THC dominant medical cannabis is the one with a dominant content of Δ-9-tetrahydrocannabinol